These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20838466)

  • 1. A novel small molecule inhibitor of hepatitis C virus entry.
    Baldick CJ; Wichroski MJ; Pendri A; Walsh AW; Fang J; Mazzucco CE; Pokornowski KA; Rose RE; Eggers BJ; Hsu M; Zhai W; Zhai G; Gerritz SW; Poss MA; Meanwell NA; Cockett MI; Tenney DJ
    PLoS Pathog; 2010 Sep; 6(9):e1001086. PubMed ID: 20838466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.
    Coburn GA; Fisch DN; Moorji SM; de Muys JM; Murga JD; Paul D; Provoncha KP; Rotshteyn Y; Han AQ; Qian D; Maddon PJ; Olson WC
    PLoS One; 2012; 7(4):e35351. PubMed ID: 22545104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
    Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
    Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of small-molecule compounds as inhibitors of HCV entry.
    Yang JP; Zhou D; Wong-Staal F
    Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
    Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
    PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimalarial ferroquine is an inhibitor of hepatitis C virus.
    Vausselin T; Calland N; Belouzard S; Descamps V; Douam F; Helle F; François C; Lavillette D; Duverlie G; Wahid A; Fénéant L; Cocquerel L; Guérardel Y; Wychowski C; Biot C; Dubuisson J
    Hepatology; 2013 Jul; 58(1):86-97. PubMed ID: 23348596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
    Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
    Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.
    Rothwangl KB; Rong L
    Virol J; 2009 Jan; 6():12. PubMed ID: 19171049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.
    Liu S; McCormick KD; Zhao W; Zhao T; Fan D; Wang T
    Hepatology; 2012 Aug; 56(2):484-91. PubMed ID: 22334503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
    Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
    EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry.
    Fraser J; Boo I; Poumbourios P; Drummer HE
    J Biol Chem; 2011 Sep; 286(37):31984-92. PubMed ID: 21768113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.
    Rothwangl KB; Manicassamy B; Uprichard SL; Rong L
    Virol J; 2008 Mar; 5():46. PubMed ID: 18355410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
    Nguyen LP; Park C; Luong TTD; Park EM; Choi DH; Han KM; Mai HN; Nguyen HC; Lim YS; Hwang SB
    Sci Rep; 2019 May; 9(1):7288. PubMed ID: 31086268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
    Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
    J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2.
    Albecka A; Montserret R; Krey T; Tarr AW; Diesis E; Ball JK; Descamps V; Duverlie G; Rey F; Penin F; Dubuisson J
    J Virol; 2011 Feb; 85(4):1777-92. PubMed ID: 21147916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles.
    Russell RS; Kawaguchi K; Meunier JC; Takikawa S; Faulk K; Bukh J; Purcell RH; Emerson SU
    J Viral Hepat; 2009 Sep; 16(9):621-32. PubMed ID: 19302336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
    Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
    Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures.
    Bush CO; Greenstein AE; Delaney WE; Beran RK
    PLoS One; 2013; 8(6):e65273. PubMed ID: 23755208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
    Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
    J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.